IMS 2022 | Current & possible uses of isatuximab in the treatment of myeloma and smoldering myeloma
Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, outlines the uses of isatuximab in the treatment of multiple myeloma and smoldering myeloma. Whilst isatuximab is now routinely used in different combinations in the relapsed/refractory (R/R) setting, it has not yet been approved in the frontline setting. Dr Cerchione highlights the possibility of incorporating this agent in quadruplet therapies, and discusses the potential of this agent in high-risk smoldering myeloma, where it is currently evaluated in combination with lenalidomide and dexamethasone vs lenalidomide and dexamethasone in the ITHACA study (NCT04270409). This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
